JP2017524382A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524382A5 JP2017524382A5 JP2017526479A JP2017526479A JP2017524382A5 JP 2017524382 A5 JP2017524382 A5 JP 2017524382A5 JP 2017526479 A JP2017526479 A JP 2017526479A JP 2017526479 A JP2017526479 A JP 2017526479A JP 2017524382 A5 JP2017524382 A5 JP 2017524382A5
- Authority
- JP
- Japan
- Prior art keywords
- mrgprb2
- mrgprx2
- isolated cell
- pharmaceutical composition
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032350P | 2014-08-01 | 2014-08-01 | |
| US62/032,350 | 2014-08-01 | ||
| PCT/US2015/043116 WO2016019246A1 (en) | 2014-08-01 | 2015-07-31 | Mrgprx2/mrgprb2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020099240A Division JP2020141708A (ja) | 2014-08-01 | 2020-06-08 | 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017524382A JP2017524382A (ja) | 2017-08-31 |
| JP2017524382A5 true JP2017524382A5 (enExample) | 2018-09-13 |
Family
ID=55218352
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526479A Pending JP2017524382A (ja) | 2014-08-01 | 2015-07-31 | 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ |
| JP2020099240A Pending JP2020141708A (ja) | 2014-08-01 | 2020-06-08 | 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020099240A Pending JP2020141708A (ja) | 2014-08-01 | 2020-06-08 | 偽アレルギー薬物反応を検出するためおよび有害反応を予防する遮断薬を同定するためのｍｒｇｐｒｘ２／ｍｒｇｐｒｂ２発現細胞ベースのアッセイ |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10696971B2 (enExample) |
| EP (1) | EP3174987B1 (enExample) |
| JP (2) | JP2017524382A (enExample) |
| CN (1) | CN107002087B (enExample) |
| AU (1) | AU2015296135A1 (enExample) |
| CA (1) | CA2957025A1 (enExample) |
| ES (1) | ES2961366T3 (enExample) |
| WO (1) | WO2016019246A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11478463B2 (en) | 2016-10-18 | 2022-10-25 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of chronic inflammatory conditions |
| EP3638793A4 (en) * | 2017-06-16 | 2021-06-09 | The Johns Hopkins University | COMPOSITIONS AND METHODS OF TREATMENT OF G-PROTEIN-LINKED RECEPTOR-MEDIATED CONDITIONS |
| CN107142325A (zh) * | 2017-06-28 | 2017-09-08 | 西安交通大学 | 一种用于药物类过敏反应敏感人群筛查的基因标志物及其应用 |
| CN108398517A (zh) * | 2018-02-11 | 2018-08-14 | 湖南正清制药集团股份有限公司 | 一种筛查正清风痛宁制剂中潜在致敏组分的方法 |
| EP3969472A1 (en) | 2019-05-16 | 2022-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat type 2 inflammation or mast-cell dependent disease |
| CN110204606B (zh) * | 2019-05-31 | 2021-04-20 | 西安交通大学 | 一种用于制备兔多克隆抗体的多肽及其应用 |
| CN110229228B (zh) * | 2019-05-31 | 2021-05-28 | 西安交通大学 | 一种对类过敏反应特异性受体mrgprx2蛋白的具有免疫原性的多肽及其应用 |
| CN110240643B (zh) * | 2019-05-31 | 2021-05-28 | 西安交通大学 | 一种用于制备类过敏反应的双抗夹心试剂盒配对抗体的多肽及其应用 |
| CN110204607B (zh) * | 2019-05-31 | 2021-04-20 | 西安交通大学 | 一种抗Mrgprx2抗体的优势抗原表位多肽及其应用 |
| CN110229227B (zh) * | 2019-05-31 | 2021-05-28 | 西安交通大学 | 一种用于制备elisa鼠单克隆包被抗体和兔多克隆检测抗体的多肽及其应用 |
| KR102494928B1 (ko) * | 2020-03-31 | 2023-02-03 | 재단법인 아산사회복지재단 | Mrgprx2를 이용한 즉시형 과민 반응 환자를 판별하는 방법 |
| CN111500708A (zh) * | 2020-05-08 | 2020-08-07 | 中南大学湘雅医院 | 一种与麻醉药物过敏相关分子标记及其应用和检测试剂盒 |
| CA3193913A1 (en) | 2020-10-06 | 2022-04-14 | Edward Brnardic | Mrgx2 antagonists |
| EP4232042A1 (en) | 2020-10-21 | 2023-08-30 | Escient Pharmaceuticals, Inc. | Modulators of mas-related g-protein receptor x2 and related products and their use |
| AU2023244778A1 (en) | 2022-03-31 | 2024-10-17 | Nippon Chemiphar Co., Ltd. | Pharmaceutical composition for preventing or suppressing or treating symptoms accompanying pseudo-allergic reactions |
| WO2023230322A1 (en) * | 2022-05-27 | 2023-11-30 | Stealth Biotherapeutics Inc. | Addressing injection site reactions associated with the administration of elamipretide |
| EP4719404A2 (en) * | 2023-05-25 | 2026-04-08 | Stealth BioTherapeutics Inc. | Methods for addressing injection site reactions associated with the administration of bevemipretide |
| CN116814689B (zh) * | 2023-06-30 | 2024-04-05 | 海湃泰克(北京)生物医药科技有限公司 | 特异性表达hMRGPRX2的转基因小鼠的构建方法及其应用 |
| CN116855503B (zh) * | 2023-08-30 | 2023-12-08 | 上海益诺思生物技术股份有限公司 | 过表达mrgprx2的稳转细胞株及其构建方法和应用 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2001011022A1 (en) | 1999-08-05 | 2001-02-15 | Smithkline Beecham Corporation | Mouse g-protein coupled receptor edg3 |
| WO2001016159A1 (en) * | 1999-08-27 | 2001-03-08 | Smithkline Beecham Corporation | Gpcr, theant |
| US7510845B2 (en) | 2000-05-04 | 2009-03-31 | California Institute Of Technology | Assay employing G protein-coupled receptor expressed in dorsal root ganglia |
| JP2002355052A (ja) | 2000-07-07 | 2002-12-10 | Takeda Chem Ind Ltd | 新規ｇ蛋白質共役型レセプター蛋白質およびそのｄｎａ |
| EP1340979A3 (en) * | 2002-02-27 | 2004-02-04 | Pfizer Limited | Neuropeptide receptor and uses thereof |
| JPWO2005028667A1 (ja) | 2003-09-19 | 2006-11-30 | 独立行政法人理化学研究所 | ヒト肥満細胞で発現するｇ蛋白質共役型受容体を標的とした薬剤およびそのスクリーニング方法 |
| JP2005304438A (ja) | 2004-04-26 | 2005-11-04 | Astellas Pharma Inc | 新規スクリーニング方法 |
| JPWO2006118328A1 (ja) * | 2005-04-28 | 2008-12-18 | 武田薬品工業株式会社 | 脱顆粒抑制剤 |
| WO2007055823A2 (en) | 2005-10-28 | 2007-05-18 | Multispan, Inc. | Gpcr expressing cell lines and antibodies |
| JP2009060787A (ja) * | 2005-11-15 | 2009-03-26 | Gunma Univ | Ｒｅｃ１６８を介する肥満細胞の脱顆粒反応を抑制する物質のスクリーニング方法及び同定方法、並びにＲｅｃ１６８アンタゴニストを含有してなる肥満細胞が関与する炎症性疾患の治療剤 |
| WO2009090190A1 (en) | 2008-01-14 | 2009-07-23 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene |
| US20120073001A1 (en) | 2008-12-01 | 2012-03-22 | The Johns Hopkins University | Methods and compositions for treating or preventing pruritis |
| JP2012178985A (ja) | 2011-02-28 | 2012-09-20 | Univ Of Tokyo | 骨量増加剤のスクリーニング方法 |
| ES2659184T3 (es) * | 2013-06-18 | 2018-03-14 | Bayer Pharma Aktiengesellschaft | Moduladores del receptor MRG |
-
2015
- 2015-07-31 AU AU2015296135A patent/AU2015296135A1/en not_active Abandoned
- 2015-07-31 EP EP15827888.7A patent/EP3174987B1/en active Active
- 2015-07-31 CN CN201580053612.XA patent/CN107002087B/zh active Active
- 2015-07-31 US US15/329,383 patent/US10696971B2/en active Active
- 2015-07-31 CA CA2957025A patent/CA2957025A1/en active Pending
- 2015-07-31 ES ES15827888T patent/ES2961366T3/es active Active
- 2015-07-31 JP JP2017526479A patent/JP2017524382A/ja active Pending
- 2015-07-31 WO PCT/US2015/043116 patent/WO2016019246A1/en not_active Ceased
-
2020
- 2020-06-05 US US16/894,363 patent/US20200370051A1/en not_active Abandoned
- 2020-06-08 JP JP2020099240A patent/JP2020141708A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ryu et al. | Fibrin drives thromboinflammation and neuropathology in COVID-19 | |
| Franks et al. | Evolution of a transcriptional regulator from a transmembrane nucleoporin | |
| Schmidt et al. | Stretch-activated two-pore-domain (K2P) potassium channels in the heart: Focus on atrial fibrillation and heart failure | |
| US20220304992A1 (en) | Methods of rejuvenating aged tissue by inhibiting 15-hydroxyprostaglandin dehydrogenase (15-pgdh) | |
| Das et al. | Trim21 regulates Nmi-IFI35 complex-mediated inhibition of innate antiviral response | |
| JP2007506426A5 (enExample) | ||
| JP2015522264A5 (enExample) | ||
| JP2019531716A5 (enExample) | ||
| Dias et al. | ANG-(3–4) inhibits renal Na+-ATPase in hypertensive rats through a mechanism that involves dissociation of ANG II receptors, heterodimers, and PKA | |
| JP2025108697A (ja) | Ａｌｔがんの処置 | |
| JP2015530868A5 (enExample) | ||
| Kommaddi et al. | Phosphorylation of the deubiquitinase USP20 by protein kinase A regulates post-endocytic trafficking of β2 adrenergic receptors to autophagosomes during physiological stress | |
| Low et al. | Emerging role of polymerase-1 and transcript release factor (PTRF/Cavin-1) in health and disease | |
| WO2009068900A3 (en) | Protein aggregation prediction systems | |
| JP2020530978A5 (enExample) | ||
| US20220143035A1 (en) | Methods for treating autoimmune or autoinflammatory disease | |
| Wen et al. | Proteome expression and carbonylation changes during Trypanosoma cruzi infection and Chagas disease in rats | |
| EP1807701A2 (en) | Gpr17 modulators, method of screening and uses thereof | |
| Jayatissa et al. | The ERVK3-1 microprotein interacts with the HUSH complex | |
| JP2013542720A5 (enExample) | ||
| WO2015134610A1 (en) | Methods for treating diabetic nephropathy | |
| JP2016520570A (ja) | Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト | |
| US20220088180A1 (en) | Immunogenic compositions and use thereof | |
| Southwood et al. | Functional analysis of frequently expressed Chinese rhesus macaque MHC class I molecules Mamu-A1* 02601 and Mamu-B* 08301 reveals HLA-A2 and HLA-A3 supertypic specificities | |
| Neethling et al. | Filamin C: a novel component of the KCNE2 interactome during hypoxia: cardiovascular topics |